Danaher's Acquisition of Genetix Group Nearly Complete | GenomeWeb

NEW YORK (GenomeWeb News) – Danaher said yesterday that it has acquired and received acceptances for approximately 97 percent of the currently issued shares of Genetix Group.

Danaher said that it intends to acquire any common shares of Genetix that remain untendered through the compulsory acquisition provisions for UK companies.

In December, Danaher, based in Washington, DC, offered to buy New Milton, UK-based Genetix Group for around ₤63.4 million ($102 million), or 85 pence per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.